PubRank

L Darryl Quarles

Author PubWeight™ 98.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006 7.53
2 Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006 3.57
3 Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006 3.36
4 How fibroblast growth factor 23 works. J Am Soc Nephrol 2007 2.92
5 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003 2.91
6 Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013 2.74
7 Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007 2.16
8 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003 2.05
9 Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012 1.97
10 Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 1.96
11 Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem 2005 1.86
12 Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011 1.74
13 GPRC6A regulates prostate cancer progression. Prostate 2011 1.68
14 GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 2008 1.63
15 Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int 2012 1.57
16 Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 2003 1.53
17 ASARM mineralization hypothesis: a bridge too far? J Bone Miner Res 2010 1.51
18 Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2009 1.45
19 Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007 1.42
20 Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 2002 1.41
21 GPRC6A mediates the non-genomic effects of steroids. J Biol Chem 2010 1.38
22 GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res 2011 1.32
23 Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005 1.30
24 Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2009 1.30
25 Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 2008 1.30
26 FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008 1.28
27 Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012 1.28
28 Calcium-sensing receptor activation of rho involves filamin and rho-guanine nucleotide exchange factor. Endocrinology 2002 1.24
29 Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 2007 1.21
30 Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 2001 1.20
31 A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012 1.20
32 Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 2007 1.19
33 Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab 2010 1.19
34 Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007 1.18
35 Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 2011 1.16
36 Calcium regulates FGF-23 expression in bone. Endocrinology 2013 1.09
37 Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix. Am J Kidney Dis 2013 1.07
38 Dose-dependent effects of Runx2 on bone development. J Bone Miner Res 2009 1.06
39 Beta-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol 2005 1.05
40 Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology 2012 1.03
41 Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem 2008 1.03
42 Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. J Cell Sci 2012 1.01
43 Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. J Biol Chem 2009 0.99
44 IRES-dependent translational control of Cbfa1/Runx2 expression. J Cell Biochem 2003 0.99
45 Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2008 0.98
46 Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem 2005 0.96
47 Inhibition of adipocyte differentiation by phytoestrogen genistein through a potential downregulation of extracellular signal-regulated kinases 1/2 activity. J Cell Biochem 2008 0.93
48 GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. Endocrinology 2012 0.93
49 Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010 0.92
50 Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest 2002 0.91
51 Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Am J Physiol Endocrinol Metab 2004 0.91
52 Osteoblast calcium-sensing receptor has characteristics of ANF/7TM receptors. J Cell Biochem 2005 0.89
53 Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab 2010 0.89
54 Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem 2012 0.87
55 A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 2004 0.87
56 Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res 2010 0.87
57 Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep 2013 0.86
58 Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues 2009 0.84
59 Inducible expression of Runx2 results in multiorgan abnormalities in mice. J Cell Biochem 2011 0.84
60 Kif3a deficiency reverses the skeletal abnormalities in Pkd1 deficient mice by restoring the balance between osteogenesis and adipogenesis. PLoS One 2010 0.84
61 Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem 2003 0.82
62 The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract 2013 0.81
63 Chronic kidney disease and diabetes mellitus predict resistance to vitamin D replacement therapy. Am J Med Sci 2013 0.80
64 Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv Exp Med Biol 2012 0.79
65 Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). J Bone Miner Res 2004 0.78
66 Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab 2014 0.77
67 RNA interference and its application in bone-related diseases. Biochem Biophys Res Commun 2007 0.77
68 Parathyroid-specific interaction of the calcium-sensing receptor and G alpha q. Kidney Int 2008 0.77
69 Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther 2002 0.76
70 Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 2015 0.76
71 Multiple faces of fibroblast growth factor-23. Curr Opin Nephrol Hypertens 2016 0.75
72 Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs. Int J Nephrol Renovasc Dis 2008 0.75
73 Calcyclin mediates serum response element (SRE) activation by an osteoblastic extracellular cation-sensing mechanism. J Bone Miner Res 2003 0.75
74 Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. Nat Clin Pract Nephrol 2006 0.75
75 Introduction: emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients. Adv Ren Replace Ther 2002 0.75
76 Oral paricalcitol: a viewpoint by james B. Wetmore and L. Darryl quarles. Treat Endocrinol 2006 0.75